Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
icosapent ethyl (vascepa) (1 trial)
Disease Progression (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Lymphoid (Phase 2)
Monoclonal Gammopathy of Undetermined Significance (Phase 2)
Multiple Myeloma (Phase 2)
Paraproteinemias (Phase 2)
Smoldering Multiple Myeloma (Phase 2)
Trials (1 total)
Trial APIs (1 total)